Evidence map›Paper›PMID 40148722›Full record

ReviewMolecular biotechnology2026

Transgenesis in Drug Discovery: Enhancing Target Identification and Validation.

Rumela Mete, Sourav Das, Arindam Saha, Sukanta Roy, Smritilekha Mondal, Anirbandeep Bose, Biswajit Basu, Gehan M Elossaily, Bhupendra Prajapati

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rumela MeteTAAB Biostudy Services, Jadavpur, Kolkata, 700032, India.
Sourav DasDepartment of Pharmaceutics, School of Pharmacy, The Neotia University, Sarisa, West Bengal, 743368, India.
Arindam SahaCognizant Technology Solutions Private Limited, Salt Lake, Kolkata, 700091, India.
Sukanta RoyDepartment of Pharmaceutics, School of Pharmacy, The Neotia University, Sarisa, West Bengal, 743368, India.
Smritilekha MondalDepartment of Biopharmaceutics, Dr. Reddy's Laboratory, Bachupally Village, Hyderabad, Telangana, 500090, India.
Anirbandeep BoseDepartment of Pharmaceutical Technology, School of Health & Medical Sciences, Adamas University, Barasat, Kolkata, West Bengal, 700126, India.
Biswajit BasuDepartment of Pharmaceutical Technology, School of Health & Medical Sciences, Adamas University, Barasat, Kolkata, West Bengal, 700126, India.
Gehan M ElossailyDepartment of Basic Medical Sciences, College of Medicine, AlMaarefa University, P.O. Box 71666, Riyadh, 13713, Saudi Arabia.
Bhupendra PrajapatiCentre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India. bhupen27@gmail.com.ORCID http://orcid.org/0000-0001-8242-4541

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transgenesis, the introduction of foreign genetic material into the genome of an organism, has become a crucial and transformative technique in the realm of drug discovery. This review article provides a comprehensive overview of the integral role that transgenesis plays in the drug discovery process, with a specific focus on target identification and target validation. By examining the recent advancements and innovative approaches, this article aims to shed light on the importance of transgenesis in accelerating drug development. In the context of target identification, transgenesis has allowed for the creation of relevant disease models, enabling researchers to study the genetic and molecular basis of various disorders. The use of transgenic animals, such as mice and zebrafish, has facilitated the identification of potential drug targets by mimicking specific human disease conditions. This review also discusses emerging technologies, such as CRISPR-Cas9 and other genome editing tools, which have revolutionized the field of transgenesis. These technologies have enhanced the precision and efficiency of genetic manipulations in transgenic animals, making the creation of disease-relevant models more accessible and cost-effective. Moreover, integration of omics technologies, such as genomics, transcriptomics, proteomics, and metabolomics, has provided a holistic view of the molecular changes in transgenic models, further aiding in target identification and validation. This review emphasizes the importance of transgenesis in target identification and validation and underscores its vital role in shaping the future of drug discovery.

Indexed as

Drug DiscoveryGene Transfer TechniquesAnimalsAnimals, Genetically ModifiedCRISPR-Cas SystemsDisease Models, AnimalGene EditingHumansMiceDrug discovery processTarget identificationTarget validationTransgenesis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.